REGULATED PRESS RELEASE published on 05/23/2025 at 07:30, 1 year 1 month ago Vif succès de l’augmentation de capital de NFL Biosciences avec une levée plafonnée à 3 millions d’euros NFL Biosciences annonce une levée de fonds réussie de 3 millions d'euros pour financer son candidat médicament contre l'addiction au tabac. Allocation des fonds pour une étude de Phase 3 de NFL-101 NFL Biosciences NFL-101 Levée De Fonds Phase 3 Addiction Au Tabac
BRIEF published on 05/22/2025 at 17:50, 1 year 1 month ago NFL Biosciences Announces €2.2 Million Capital Increase NFL Biosciences Clinical Trials Capital Increase Biopharmaceuticals Investment Risks
BRIEF published on 05/22/2025 at 17:50, 1 year 1 month ago NFL Biosciences annonce une levée de fonds de 2,2 millions d'euros Augmentation De Capital NFL-101 Levée De Fonds Phase 3 Plateforme PrimaryBid
REGULATED PRESS RELEASE published on 05/22/2025 at 17:45, 1 year 1 month ago NFL Biosciences lance une levée de fonds d’environ 2,2 millions d’euros par voie d’augmentations de capital NFL Biosciences lance une levée de fonds de 2,2 millions d'euros pour étude sur le traitement des addictions avec nouveau médicament NFL-101 NFL Biosciences NFL-101 Levée De Fonds Addictions Étude Phase 3
REGULATED PRESS RELEASE published on 05/22/2025 at 17:45, 1 year 1 month ago NFL Biosciences launches a capital increase of approximately €2.2 million NFL Biosciences launches a €2.2 million capital increase through global offering for smoking cessation drug development. Subscription price: €1.20/share NFL Biosciences Capital Increase Smoking Cessation Subscription Price Global Offering
BRIEF published on 05/21/2025 at 17:50, 1 year 1 month ago Résultats de l'Assemblée Générale de NFL Biosciences NFL Biosciences Actionnaires Assemblée Générale Biopharmaceutique Resolutions
BRIEF published on 05/21/2025 at 17:50, 1 year 1 month ago NFL Biosciences General Meeting Results NFL Biosciences Shareholders Biopharmaceuticals Resolutions General Assembly
REGULATED PRESS RELEASE published on 05/21/2025 at 17:45, 1 year 1 month ago NFL Biosciences : compte rendu de l’assemblée générale mixte du 21 mai 2025 Compte rendu de l'assemblée générale mixte de NFL Biosciences du 21 mai 2025. Résolutions approuvées pour le développement de médicaments botaniques innovants pour traiter les addictions NFL Biosciences Médicaments Botaniques Assemblée Générale Mixte Résolutions Approuvées Addictions
BRIEF published on 05/12/2025 at 08:35, 1 year 1 month ago NFL Biosciences Restructures Scientific Committee for NFL-101 Advancement NFL Biosciences NFL-101 Phase 3 Trials Tobacco Addiction Scientific Committee
BRIEF published on 05/12/2025 at 08:35, 1 year 1 month ago NFL Biosciences renforce son Comité Scientifique pour le développement de NFL-101 NFL Biosciences NFL-101 Phase 3 Addiction Tabac Comité Scientifique
Published on 06/25/2026 at 00:30, 4 hours 14 minutes ago Northern Dynasty Reports Annual General Meeting Results and Welcomes New Directors
Published on 06/24/2026 at 23:05, 5 hours 39 minutes ago Polaris Modifies Quorum Requirement for Upcoming AGM
Published on 06/24/2026 at 22:15, 6 hours 29 minutes ago Organto Foods Announces Annual General Meeting Results
Published on 06/24/2026 at 21:20, 7 hours 24 minutes ago Taranis to Explore New Properties East of Thor Mineral Resource
Published on 06/24/2026 at 20:10, 8 hours 34 minutes ago Fox River Obtains Final Order Approving Plan of Arrangement With Avenir Minerals Limited
Published on 06/25/2026 at 03:20, 1 hour 24 minutes ago ZTT at Intersolar Europe 2026: Full-Industry-Chain Strength Powering a Low-Carbon Future
Published on 06/24/2026 at 23:57, 4 hours 47 minutes ago OHB: Upsized private placement worth EUR 900 million successfully completed
Published on 06/24/2026 at 20:54, 7 hours 49 minutes ago EQS-Adhoc: Branicks Group AG sets out timetable for the publication of its 2025 annual and consolidated financial statements
Published on 06/24/2026 at 19:00, 9 hours 44 minutes ago ALTAREA - Succès de l’option pour le paiement du dividende en actions : taux de souscription de 78,5 %
Published on 06/24/2026 at 18:00, 10 hours 44 minutes ago KERLINK : Assemblée générale mixte des actionnaires du 23 juin 2026 Seconde convocation le 9 juillet 2026.
Published on 06/24/2026 at 17:45, 10 hours 59 minutes ago Air Liquide poursuit son développement au Kazakhstan avec un investissement clé pour le complexe industriel de Silleno
